16023-99-7

Upstream product

• 2555-30-8 7-hydroxy-4-phenylcoumarin 
• 16024-13-8 7-(allyloxy)-4-phenyl-2H-chromen-2-one 

Downstream Products

• 96567-73-6 4-phenyl-6-dimethylaminomethyl-7-hydroxy-8-allylcumarin hydrochloride 
• 96567-91-8 4-phenyl-6-(4-morpholinylmethyl)-7-hydroxy-8-allylcumarin hydrochloride 

Relevant academic research and scientific papers

Synthesis and anti-proliferative activity of novel oxepin-annulated coumarins

A series of fused dihydrooxepino[h]- and dihydrooxepino[g]coumarins (7 and 8) were synthesized through allylation, Claisen rearrangement, allylation and ring-closing metathesis (RCM), respectively. All the synthesized compounds were characterized by appropriate spectral analysis. The anti-proliferative activities of compound 5a-c, 6a, 6c, 7a-c and 8a-c were evaluated against human colon cancer (Caco-2), liver cancer (HepG2) and breast cancer (SKBR-3) cell lines using tamoxifen (TAM) as the positive control. Compound 7b showed significant anti-proliferative activity against resistant Caco-2 and SKBR-3 cell lines on comparison with all other coumarin derivatives. Interestingly, compound 8b was more potent than TAM against sensitive HepG2 cell line.

Ring-closing-metathesis-based synthesis of annellated coumarins from 8-allylcoumarins

8-Allylcoumarins are conveniently accessible through a microwave-promoted tandem Claisen rearrangement/Wittig olefination/ cyclization sequence. They serve as a versatile platform for the annellation of five- to seven-membered rings using ring-closing ole

Benzopyranone and quinolone inhibitors of ras farnesyl transferase

The present invention provides ras farnesyl transferase inhibiting compounds of Formula I The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula I.